← Back to patent-cliff list
Pegmolesatide
Tier C — Watch / tradePegmolesatide
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EpoR
Indications (approved)：Chronic renal impairment, Anaemia
Regional status
US
-
EU
-
China
Approved
2023-06-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pegmolesatide?
Approved indications include: Chronic renal impairment, Anaemia.
When does the Pegmolesatide patent expire?
No public expiry year is available for Pegmolesatide yet; this page updates once verified.
How do I get a quote for Pegmolesatide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27